HemoSonics Wins Best Medical Device Company in Triangle Business Journal's 2025 Life Sciences Awards
"Innovation is at the heart of what we do at HemoSonics, and we're thrilled to be mentioned alongside other Research Triangle Park companies who are changing the world for the better through medical and scientific advances."
Share
According to data from the North Carolina Biotechnology Center, North Carolina is home to 840 life sciences companies, with the lion's share based in the Triangle. The Triangle Business Journal's Life Sciences Awards recognize 12 individuals and research organizations from the Research Triangle, North Carolina (Raleigh, Durham and Chapel Hill region) that are leading and breaking ground in this field. The broad spectrum of the life sciences arena encompasses biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and other related fields.
The HemoSonics Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer, along with QPlus and QStat Cartridges. The System provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in under 15 minutes, empowering clinicians with information to inform patient-centered decisions that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample.
HemoSonics' Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program.
'The Research Triangle Park has long been recognized as a catalyst for pioneering technologies in biotechnology, medical devices, and health technology, and this community is one of the key reasons we chose Durham for our headquarters,' said Bob Roda, HemoSonics President and CEO. 'Innovation is at the heart of what we do at HemoSonics, and we're thrilled to be mentioned alongside companies who are changing the world for the better through medical and scientific advances.'
HemoSonics' Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America.
About HemoSonics:
HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management.
Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit HemoSonics.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
7 days ago
- Forbes
A Practical Look At How To Solve The Blood Supply Problem
Bob Roda is the President and CEO of Hemosonics. Many people are familiar with food deserts—areas where it is difficult to obtain fresh, healthy food like produce and vegetables—but far fewer are familiar with blood deserts, places where blood supplies are scarce or even sometimes nonexistent. According to a recent article published by Harvard Medical School, "Billions of people live in 'blood deserts,' areas in which the clinical need for blood components cannot be met in at least 75 percent of cases." A blood shortage could prove disastrous in life-threatening cases where a patient needs blood in minutes. Blood deserts aren't just located abroad; numerous rural communities in the U.S. don't have access to crucial blood supplies. Many groups, including the Blood D.E.S.E.R.T. Coalition, have organized to combat the challenge. Hospitals and healthcare organizations, such as the Red Cross, have responded with additional calls for blood donations. While blood donations provide a crucial pipeline for blood supplies, they cannot fix the problem. Emerging technology, hospital culture change and community activism, however, could provide critical help in the short term as experts work on systemic changes to boost blood supply in challenged areas. Experts say it will take decades to recover from the blood shortage in the U.S. alone. Here are four short-term strategies to adopt now to help address blood deserts. 1. Change the culture of thinking around transfusions. Transfusions are a critical life-saving resource, particularly for victims of severe body trauma like industrial accidents and automobile wrecks. However, many have made strong arguments that transfusions are overused. In reality, transfusion is often unnecessary, and patients will do fine with their own blood. There are challenges to this, like longstanding medical practices. But when a transfusion is avoided, blood is saved for a patient who needs it. 2. Embrace patient blood management (PBM). Four years ago, the World Health Organization (WHO) called for healthcare systems worldwide to implement patient blood management (PBM) as a standard of care. The adoption of PBM continues to lag, however, particularly in U.S. hospitals. In short, PBM is a systematic, evidence-based approach that improves patient outcomes by preserving a patient's own blood and promoting safety and empowerment. PBM has three critical tenets: Use the patient's blood, minimize blood loss and improve a patient's anemia tolerance. Patient blood management has been transformative in conserving blood supplies at hospitals worldwide. The only challenge is changing the existing medical culture and protocols around blood use and transfusion. Hospitals should embrace the practice to increase blood supplies. 3. Adopt new technologies. Technological advances and new tools may offer the best chance to help underdeveloped blood deserts in the short term. Chief among them are viscoelastic testing systems. These tests identify whether a patient is at risk for bleeding, the type of blood product they may require and the amount of blood needed. (Full disclosure: My company, HemoSonics, manufactures Quantra, a viscoelastic testing system.) One of the most frequent causes of hospital trauma death is uncontrolled bleeding. However, many of these fatalities are potentially preventable with early, targeted hemostatic intervention. Some technological obstacles include the initial cost of purchasing the technology and training. However, according to the WHO, hospitals that implement viscoelastic testing find they quickly preserve blood, improve patient outcomes, reduce hospital readmissions and reoperations and lower hospital and healthcare facility costs. Other new technologies could also make a difference. Zipline, for example, delivers blood and other critical medical supplies via drones from hospitals and urban areas to blood deserts in Rwanda. There are also 'walking blood banks': new backpack-size kits that contain everything remote medical personnel need to collect and then transfuse blood. Finally, AI and machine learning are also promising: What they do exceedingly well is identify patterns and data and extract crucial findings about blood usage. The findings enable blood banks to allocate resources more effectively and earmark blood donations for underserved areas. AI can also help quickly match a patient with available blood supply, minimizing labor and ensuring patients receive the necessary blood product fast. 4. Utilize mobile blood collection. When blood is collected, it is typically transported to a central site in an urban area for safe storage. Another promising answer to blood deserts is a more targeted use of blood donations. For example, patients in certain areas organize to collect blood for a remote hospital in need. Blood supplies could also be collected and then earmarked for geographic areas where supplies are scarce. Blood donors could also be identified and contacted during a critical regional shortage. The existence of blood deserts is a multilayered social and economic problem that has as much to do with fundamental economic inequities as it does with medical practices. Truly fixing blood deserts will require economic development, improving transportation and supply chains and ensuring an equitable allocation of resources. Nonetheless, the practices above shouldn't be considered just a short-term fix, but rather part of a collective effort to eradicate blood deserts. Combining technology, strategy, activism and public service is a major step in the right direction to conserve blood supplies and address the problem. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
17-07-2025
- Yahoo
HemoSonics Wins 2025 Supplier Horizon Award from Premier, Inc.
One of 13 companies to receive Premier, Inc.'s Supplier Horizon Award for excellence in improving healthcare performance, HemoSonics' Quantra Hemostasis System provides comprehensive hemostasis analysis in less than 15 minutes DURHAM, N.C., July 17, 2025--(BUSINESS WIRE)--HemoSonics LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Supplier Horizon Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. HemoSonics was honored for its Quantra Hemostasis System, an advanced viscoelastic testing device that accelerates decision-making, enhances patient outcomes and reduces healthcare costs by delivering rapid, actionable coagulation assessments in near real-time. One of 13 suppliers to receive the award this year, HemoSonics was recognized for its support of Premier members through exceptional local customer service and engagement, as well as value creation through clinical excellence and a commitment to lower costs. Supplier Horizon Award winners are selected by Premier member committees and have a tenure of less than three years as a Premier contracted supplier. HemoSonics' Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges. The Quantra System utilizes innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that measures the coagulation properties of a whole blood sample, providing comprehensive coagulation analysis in under 15 minutes. Doctors receive test results quickly during critical and complex surgeries, enabling timely, patient-centered decisions about bleeding management, which improves care and optimizes the use of blood products. "Our mission is to ensure that our clinician partners receive accurate test results quickly during critical, complex surgeries that allow them to make timely patient-centered clinical decisions. By doing so, patients can receive the care that they need at the moment that they need it. We will continue to work tirelessly to ensure that our customers and partners are supported, as we partner with hospitals to deliver better patient outcomes, all while lowering the cost of care," said HemoSonics President and CEO Bob Roda. "We are humbled and proud to receive the Supplier Horizon Award from Premier, Inc." HemoSonics' Quantra System is FDA-cleared for use in cardiovascular and major orthopedic surgery, trauma, and liver transplantation. It requires minimal resources to maintain, is easy to operate and interpret results, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. According to a 2023 Journal of Cardiothoracic Surgery study, Quantra reduced blood component use between 10% and >90%. In addition, the cost of blood products decreased by 41%. "HemoSonics supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize HemoSonics as a Supplier Horizon Award recipient." The Supplier Horizon Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition, July 15-17, 2025. About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's ease of use and fast interpretation of results enable simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit to learn more. View source version on Contacts Media Contacts: Mindy M. HullMercury Global Partners for HemoSonics+1 415 889 9977 (San Francisco)hemosonics@ Michael Held-HernandezMercury Global Partners for HemoSonics+1 480 306 1154 (Washington D.C.)hemosonics@
Business Journals
18-06-2025
- Business Journals
Micropep partners with Corteva to develop crop protections
2025 40 Under 40 Awards For the 25th year Triangle Business Journal will recognize 40 of the Triangle's best and brightest business and community leaders- all under the age of 40!
